Category: Money tips Release Date: 2007-07-19
Source: Source up to invest in
The development of Tianjin Binhai New Area has become the focus of attention, Tianjin Mayor Dai September 9, said comprehensive reform of Binhai New Area the focus of recent work is to encourage financial reform and innovation, and focus on the reform of China's current financial difficulties, the focus for a breakthrough that the state's strong support for the construction of Binhai New Area's attitude. G-day drugs (600,488) registered in Binhai New Area Tianjin New Technology Industrial Park, is a state-certified high-tech enterprise, it is the first company in Tianjin completed the split share structure reform of listed companies. It had won the Tianjin Municipal Government strongly support, enjoy 15% income tax incentives. Not long ago, the company and the Tianjin Science and Technology Leading Group Office of the special fund for innovation in the signing of an agreement, the company will receive a special fund for scientific and technological innovation, the total amount of 10 million yuan, is the Government of Tianjin in this special fund for scientific and technological innovation the largest single item. The money is the company's annual output of 500 tons of hormones Pharmaceuticals Intermediates, "3029" project earmarked for scientific research and development funds by the company free use, in the end of December 2005 and 2007 phases in place, while the first phase of three million funds have been in place, future development prospects are extremely good.
G-day drugs (600,488) Company for the leading pharmaceutical company, is Asia's largest corticosteroid drugs research and development, production and export base and international market share, ranking third in the world. To the company so far to pass, including the world's largest pharmaceutical company Pfizer Inc. and Glaxo's second-largest U.S. pharmaceutical companies, including eight multinational pharmaceutical companies on-site quality audit, as the U.S. Pfizer, Glaxo . SmithKline, the British jalhay, France, Sanofi and other large multinational companies qualified suppliers, and has seven of them established a supply and demand. The next five years, Pfizer plans to innovation in China's listed 15 drugs, drugs will be the natural days of its partners, to share a few trillion medical business. The company's strong international competitiveness of products, the main products include series of dexamethasone, prednisone series, betamethasone, cortisone series of bulk drugs such as corticosteroids, including dexamethasone in the domestic market share of about 70%, in addition to Asia outside of China for more than 50% market share, and to enter the European market. 2006 companies will have more than 10 products have U.S. FDA and European COS certification. To achieve an annual export volume reached 40 million U.S. dollars more than exports products account for 50% of sales revenue.
The company also with Tianjin Pharmaceutical Group, in the Tianjin Economic and Technological Development Zone West a total investment of 2.1 billion to build industrial park in Tianjin Jin-yao bio-engineering, will be formed from starting material to the preparation of the end product industry chain structure, and develop a recycling economy, showing that the company's will greatly benefit from Tianjin Sea region's future high-speed development, the future company's prospects for the future.
The secondary market, the recent concept of Binhai New Area can be described as extremely hot stocks, compared to the same important for the coastal section of one of the leading performance in a very low-key G-day medicine, there is a strong compensatory growth requirements. The Unit diluted share reform launched a wave of bodies quickly grab the first chip market, then began to adjust to follow the broader market has now returned to pre-bottom of the region, Xi Pan is very full, afternoon is expected to substantially counter-offensive, investors attention.
